CD79-Specific Chimeric Antigen Receptor, Autolus Limited
Summary
The European Patent Office published patent application EP3793688A1, granting Autolus Limited exclusive rights to a CD79-specific chimeric antigen receptor (CAR) for therapeutic applications. The patent names five inventors and designates thirty-nine contracting states across Europe. As a published European patent, the instrument grants enforceable intellectual property rights to the applicant while third parties must consider licensing or design-around strategies to avoid infringement.
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 34 changes logged to date.
What changed
The European Patent Office issued publication EP3793688A1 for a CD79-specific chimeric antigen receptor developed by Autolus Limited, with inventors including Martin Pulé, Shaun Cordoba, Simon Thomas, Shimobi Onuoha, and Mathieu Ferrari. The patent application covers the CAR construct and its therapeutic applications, classified under IPC codes including A61P 35/02 and C07K 16/28.
Competitors developing CAR-T cell therapies targeting CD79 should review the claims of this granted European patent and consider whether licensing, validity challenges, or design-around strategies are necessary. The patent designates thirty-nine European contracting states, providing broad territorial protection for Autolus in the CAR therapeutic space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A CD79-SPECIFIC CHIMERIC ANTIGEN RECEPTOR
Publication EP3793688A1 Kind: A1 Apr 15, 2026
Applicants
Autolus Limited
Inventors
PULÉ, Martin, CORDOBA, Shaun, THOMAS, Simon, ONUOHA, Shimobi, FERRARI, Mathieu
IPC Classifications
A61P 35/02 20060101AFI20191122BHEP A61K 48/00 20060101ALI20191122BHEP A61K 35/17 20150101ALI20191122BHEP C07K 16/28 20060101ALI20191122BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.